Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Pacific Biosciences of California Inc’s stock clocked out at $0.96, down -7.34% from its previous closing price of $1.04. In other words, the price has decreased by -$7.34 from its previous closing price. On the day, 11.52 million shares were traded.
Ratios:
To gain a deeper understanding of PACB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.87 and its Current Ratio is at 6.68. In the meantime, Its Debt-to-Equity ratio is 7.63 whereas as Long-Term Debt/Eq ratio is at 7.60.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Farmer Michele sold 5,195 shares for $1.00 per share. The transaction valued at 5,200 led to the insider holds 269,259 shares of the business.
HENRY CHRISTIAN O sold 12,497 shares of PACB for $17,583 on Mar 03 ’25. The insider now owns 2,225,357 shares after completing the transaction at $1.41 per share. On Mar 03 ’25, another insider, Van Oene Mark, who serves as the insider of the company, sold 6,486 shares for $1.41 each. As a result, the insider received 9,126 and left with 1,497,695 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.90 while its Price-to-Book (P/B) ratio in mrq is 3.16.
Stock Price History:
Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -16.67%, while the 200-Day Moving Average is calculated to be -39.71%.
Shares Statistics:
A total of 300.04M shares are outstanding, with a floating share count of 264.16M. Insiders hold about 11.97% of the company’s shares, while institutions hold 65.69% stake in the company.
Earnings Estimates
The current market rating for Pacific Biosciences of California Inc (PACB) reflects the collective analysis of 11.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.13 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.58 and -$0.68 for the fiscal current year, implying an average EPS of -$0.63. EPS for the following year is -$0.5, with 12.0 analysts recommending between -$0.38 and -$0.62.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $36.35M. It ranges from a high estimate of $37.3M to a low estimate of $34M. As of the current estimate, Pacific Biosciences of California Inc’s year-ago sales were $36.01MFor the next quarter, 10 analysts are estimating revenue of $39.71M. There is a high estimate of $42M for the next quarter, whereas the lowest estimate is $37.9M.
A total of 12 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $160.2M, while the lowest revenue estimate was $150.28M, resulting in an average revenue estimate of $155.78M. In the same quarter a year ago, actual revenue was $154.01MBased on 13 analysts’ estimates, the company’s revenue will be $185.1M in the next fiscal year. The high estimate is $200.8M and the low estimate is $164.53M.
